Abstract: The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding, prolonged bleeding, altered bleeding pattern, dysmenorrhea, as well as of the underlying diseases leiomyoma and endometriosis and the use of the agent to inhibit menstruation. Furthermore, the invention provides novel IL-11 antibodies.

Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Abstract: An electrochemical actuator forms a sealed gas space inside of which there are a plurality of cells. Each cell has a solid electrode made from an electrochemically reversibly oxidizable material and a counter electrode. By applying a reversible direct current, an electrochemical reaction is initiated which results in a pressure increase or decrease in the gas space that can be used for generating movement. The manufacture of the actuator is simplified and manufacturing costs are lowered by providing a stackable spacer frame for each cell which is constructed of a material that is a relatively good heat conductor and an electric isolator. The rim of a metallic cell cup is attached to the spacer frame and a matrix soaked with an electrolyte is placed inside the cup. Each cell further has a solid electrode, a separator and a counter electrode which, together with the spacer frame, are assembled into a cell.